These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 1725238)
41. Does the HIV envelope induce a chronic graft-versus-host-like disease? Habeshaw J; Hounsell E; Dalgleish A Immunol Today; 1992 Jun; 13(6):207-10. PubMed ID: 1627248 [TBL] [Abstract][Full Text] [Related]
42. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034 [TBL] [Abstract][Full Text] [Related]
43. Enzyme immunoassay using native envelope glycoprotein (gp160) for detection of human immunodeficiency virus type 1 antibodies. Nair BC; Ford G; Kalyanaraman VS; Zafari M; Fang C; Sarngadharan MG J Clin Microbiol; 1994 Jun; 32(6):1449-56. PubMed ID: 8077388 [TBL] [Abstract][Full Text] [Related]
44. Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen. VanCott TC; Veit SC; Kalyanaraman V; Earl P; Birx DL J Immunol Methods; 1995 Jun; 183(1):103-17. PubMed ID: 7602128 [TBL] [Abstract][Full Text] [Related]
45. Prediction of HIV peptide epitopes by a novel algorithm. Roberts CG; Meister GE; Jesdale BM; Lieberman J; Berzofsky JA; De Groot AS AIDS Res Hum Retroviruses; 1996 May; 12(7):593-610. PubMed ID: 8743085 [TBL] [Abstract][Full Text] [Related]
46. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Cooney EL; McElrath MJ; Corey L; Hu SL; Collier AC; Arditti D; Hoffman M; Coombs RW; Smith GE; Greenberg PD Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1882-6. PubMed ID: 8446603 [TBL] [Abstract][Full Text] [Related]
47. High-titer HIV-1 neutralizing antibody response of rhesus macaques to gp160 and env peptides. Ronco J; Dedieu JF; Marie FN; Pinter A; Kaczorek M; Girard M AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1117-23. PubMed ID: 1503824 [TBL] [Abstract][Full Text] [Related]
48. Characterization of monoclonal antibodies identifying type and strain-specific epitopes of human immunodeficiency virus type 1. Robert V; Resnicoff M; Chermann JC; Devaux C Mol Cell Biochem; 1991 Apr; 102(2):115-23. PubMed ID: 1715507 [TBL] [Abstract][Full Text] [Related]
49. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059 [TBL] [Abstract][Full Text] [Related]
50. Characterization of monoclonal antibodies to human immunodeficiency virus type 2 envelope glycoproteins. Traincard F; Rey-Cuillé MA; Huon I; Dartevelle S; Mazié JC; Benichou S AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1659-67. PubMed ID: 7888225 [TBL] [Abstract][Full Text] [Related]
51. Antigenicity of linear and cyclic peptides mimicking the disulfide loops in HIV-2 envelope glycoprotein: synthesis, reoxidation and purification. Belhadj Jrad B; Bahraoui E J Pept Res; 1998 May; 51(5):370-85. PubMed ID: 9606017 [TBL] [Abstract][Full Text] [Related]
52. Linear and cyclic peptides mimicking the disulfide loops in HIV-2 envelope glycoprotein induced antibodies with different specificity. Jrad BB; Bahraoui E Mol Immunol; 1997; 34(16-17):1177-89. PubMed ID: 9566765 [TBL] [Abstract][Full Text] [Related]
53. Comprehensive T-cell epitope mapping of HIV-1 env antigens reveals many areas recognized by HIV-1-seropositive and by low-risk HIV-1-seronegative individuals. Mutch D; Underwood J; Geysen M; Rodda S J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):879-90. PubMed ID: 7519672 [TBL] [Abstract][Full Text] [Related]
54. Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus. Hansen JE; Nielsen C; Arendrup M; Olofsson S; Mathiesen L; Nielsen JO; Clausen H J Virol; 1991 Dec; 65(12):6461-7. PubMed ID: 1719230 [TBL] [Abstract][Full Text] [Related]
55. Carbohydrates of human immunodeficiency virus. Hansen JE APMIS Suppl; 1992; 27():96-108. PubMed ID: 1520531 [TBL] [Abstract][Full Text] [Related]
56. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. Srivastava IK; VanDorsten K; Vojtech L; Barnett SW; Stamatatos L J Virol; 2003 Feb; 77(4):2310-20. PubMed ID: 12551968 [TBL] [Abstract][Full Text] [Related]
57. Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins. Neurath AR; Jiang S; Strick N; Kolbe H; Kieny MP; Muchmore E; Girard M AIDS Res Hum Retroviruses; 1991 Oct; 7(10):813-23. PubMed ID: 1720628 [TBL] [Abstract][Full Text] [Related]
58. Gp160 of commercial HIV western blots is not gp160env. Should criteria for seropositivity be revised? Fenouillet E; Blanes N; Gluckman JC AIDS; 1991 Jun; 5(6):770. PubMed ID: 1883550 [No Abstract] [Full Text] [Related]
59. Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1. Langedijk JP; Back NK; Kinney-Thomas E; Bruck C; Francotte M; Goudsmit J; Meloen RH Arch Virol; 1992; 126(1-4):129-46. PubMed ID: 1381908 [TBL] [Abstract][Full Text] [Related]
60. Humoral immune responses in human HIV-1 infection clearance of initial burst of virus replication and protection against disease progression. Goudsmit J Int Rev Immunol; 1992; 8(1):65-81. PubMed ID: 1374113 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]